"2022 was a momentous year for Dyne and our commitment to the rare muscle disease community as we advanced not one, but two programs from our FORCE platform into clinical trials. This exciting transition into a clinical-stage company required important work across the organization to engage with individuals and families living with DM1 and DMD, clinicians treating these diseases, regulators and other stakeholders," said Joshua Brumm, president and chief executive officer of Dyne. "We remain focused on driving to meaningful clinical data readouts for our ACHIEVE and DELIVER trials anticipated in the second half of 2023, including evaluating key biomarkers of dystrophin in DMD and splicing in DM1. With cash runway expected through 2024 and strong fundamentals across the business, we believe we are well positioned to achieve our near-term milestones and to advance our mission of delivering life-transforming therapies for people with serious muscle diseases."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Oppenheimer starts Dyne Therapeutics at Outperform with $34 price target
- Dyne Therapeutics initiated with an Outperform at Oppenheimer
- TipRanks ‘Perfect 10’ List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks
